Can fewer radiation sessions be safer for lung cancer?
NCT ID NCT07777614
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This trial is testing two different radiation schedules for people with peripheral lung cancer or a single lung metastasis. One group receives the standard five-session treatment, while the other gets an experimental three-session approach. The goal is to see if the shorter schedule causes fewer severe side effects while still controlling the tumor. The study includes adults with inoperable tumors who are fit enough for treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Image-guided stereotactic ablative radiotherapy (SABR) given in either 3 or 5 sessions
- What this could lead to
- If successful, this could help tailor radiation dosing for lung cancer, reducing side effects while maintaining tumor control.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The shorter 3-fraction schedule might not be as safe or effective as the standard 5-fraction approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St Luke's Radiation Oncology Network (SLRON) at St Luke's Hospital and St James's Hospital
Dublin, D06 HH36, Ireland
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Brain chemo route outsmart resistant lung cancer?
- Can a precise Lung-Sparing surgery beat standard lobectomy for early lung cancer?
- Can lattice radiation boost immunotherapy to shrink lung tumors before surgery?
- Can a targeted pill boost lung cancer treatment?
- Seeing the immune battle inside lung tumors: a new imaging tracer under the microscope
- Can a targeted pill offer hope for stubborn lung cancer?